(Trends Wide)– Vaccine advisers at the U.S. Centers for Disease Control and Prevention (CDC) voted unanimously, 11-0, on Friday in favor of recommending booster doses of the vaccine against Pfizer / BioNTech and Moderna covid-19 for all adults age 18 and older, six months after completing their primary two-dose regimen.
Members of the CDC Advisory Committee on Immunization Practices (ACIP) heard details of data showing that adverse events after booster vaccines were even more rare than after people received both. first doses of Moderna or Pfizer vaccines. The most common were injection site pain, headache, and tiredness.
The US Food and Drug Administration granted emergency use authorization for the boosters earlier this Friday and the ACIP had scheduled the meeting in advance of the decision. Now it will be up to the director of the CDC, Dr. Rochelle Walensky, to give the final go-ahead.
Most Americans were already eligible for booster doses. The FDA and CDC had approved the administration of boosters to all people age 65 and older and to many people age 18 and older at high risk of serious infection six months after completing the Moderna and Pfizer primary series of vaccines. The FDA also authorized boosters for all people who received one of Johnson & Johnson’s single-dose Janssen vaccines at least two months prior, and the CDC already says those people should receive a booster.
This Friday’s vote simplifies targeting, making it clear that all adults should or may receive a booster six months after completing the first two doses.
Moderna’s booster is a half dose of your vaccine or 50 micrograms. The Pfizer booster is a full dose or 30 micrograms. More than 31 million Americans have already received a booster dose, about 17% of fully vaccinated adults.
(Trends Wide)– Vaccine advisers at the U.S. Centers for Disease Control and Prevention (CDC) voted unanimously, 11-0, on Friday in favor of recommending booster doses of the vaccine against Pfizer / BioNTech and Moderna covid-19 for all adults age 18 and older, six months after completing their primary two-dose regimen.
Members of the CDC Advisory Committee on Immunization Practices (ACIP) heard details of data showing that adverse events after booster vaccines were even more rare than after people received both. first doses of Moderna or Pfizer vaccines. The most common were injection site pain, headache, and tiredness.
The US Food and Drug Administration granted emergency use authorization for the boosters earlier this Friday and the ACIP had scheduled the meeting in advance of the decision. Now it will be up to the director of the CDC, Dr. Rochelle Walensky, to give the final go-ahead.
Most Americans were already eligible for booster doses. The FDA and CDC had approved the administration of boosters to all people age 65 and older and to many people age 18 and older at high risk of serious infection six months after completing the Moderna and Pfizer primary series of vaccines. The FDA also authorized boosters for all people who received one of Johnson & Johnson’s single-dose Janssen vaccines at least two months prior, and the CDC already says those people should receive a booster.
This Friday’s vote simplifies targeting, making it clear that all adults should or may receive a booster six months after completing the first two doses.
Moderna’s booster is a half dose of your vaccine or 50 micrograms. The Pfizer booster is a full dose or 30 micrograms. More than 31 million Americans have already received a booster dose, about 17% of fully vaccinated adults.